Rachlin Evan Lockwood, a director at Iambic Therapeutics, Inc., has reported substantial stock transactions that could influence both the company and the broader biological products industry. The filings indicate a series of acquisitions and conversions involving millions of shares, demonstrating a proactive approach to investment and ownership.
Background
Iambic Therapeutics, Inc. operates in the biological products sector, specifically focusing on products that do not include diagnostic substances. The company is based in San Diego, California, and is publicly traded under the ticker symbol IAM. Recent filings show Lockwood's active role in the company, with multiple transactions reported in a short period.
What the Filing Says
The recent filing, accession number 0002151678-26-000007, details several significant transactions by Lockwood. On October 16, 2026, he acquired 1,458,736 shares of common stock and an additional 410,762 shares, bringing his total ownership to 1,869,498 shares. Additionally, Lockwood converted 1,152,025 shares of Series B Convertible Preferred Stock into common stock, along with other transactions involving convertible promissory notes and preferred stock.
Impact
These transactions may affect various stakeholders, including investors and other directors at Iambic Therapeutics. Lockwood's actions could signal confidence in the company's future, potentially influencing other investors' decisions and the company's overall market perception.
What's Next
The filing does not say what happens next.